Where Is Buprenorphine Dispensed to Treat Opioid Use Disorders? The Role of Private Offices, Opioid Treatment Programs, and Substance Abuse Treatment Facilities in Urban and Rural Counties
- PMID: 26350930
- PMCID: PMC4567853
- DOI: 10.1111/1468-0009.12137
Where Is Buprenorphine Dispensed to Treat Opioid Use Disorders? The Role of Private Offices, Opioid Treatment Programs, and Substance Abuse Treatment Facilities in Urban and Rural Counties
Abstract
Policy points: Buprenorphine is an effective opioid dependence treatment that has expanded access to care since its 2002 approval, but it can only be prescribed by physicians waivered to treat a limited number of individuals. We examined the impact of 2006 legislation that increased waivered physician patient limits from 30 to 100 on buprenorphine use, and found that 100-patient-waivered physicians were significantly associated with growth in buprenorphine use, with no such relationship for 30-patient-waivered physicians. Policies relaxing patient limits may be more effective in increasing buprenorphine use than alternatives such as opening new substance abuse treatment facilities or increasing the overall number of waivered physicians.
Context: Opioid use disorders are a significant public health problem. In 2002, the FDA approved buprenorphine as an opioid use disorder treatment when prescribed by waivered physicians who were limited to treating 30 patients at a time. In 2006, federal legislation raised this number to 100 patients. Although federal legislators are considering increasing these limits further and expanding prescribing privileges to nonphysicians, little information is available regarding the impact of such changes on buprenorphine use. We therefore examined the impact of the 2006 legislation-as well as the association between urban and rural waivered physicians, opioid treatment programs, and substance abuse treatment facilities-on buprenorphine distributed per capita over the past decade.
Methods: Using 2004-2011 state-level data on buprenorphine dispensed and county-level data on the number of buprenorphine-waivered physicians and substance abuse treatment facilities using buprenorphine, we estimated a multivariate ordinary least squares regression model with state fixed effects of a state's annual total buprenorphine dispensed per capita as a function of the state's number of buprenorphine providers.
Findings: The amount of buprenorphine dispensed has been increasing at a greater rate than the number of buprenorphine providers. The number of physicians waivered to treat 100 patients with buprenorphine in both rural and urban settings was significantly associated with increased amounts of buprenorphine dispensed per capita. There was no significant association in the growth of buprenorphine distributed and the number of physicians with 30-patient waivers.
Conclusions: The greater amounts of buprenorphine dispensed are consistent with the potentially greater use of opioid agonists for opioid use disorder treatment, though they also make their misuse more likely. The changes after the 2006 legislation suggest that policies focused on increasing the number of patients that a single waivered physician could safely and effectively treat could be more effective in increasing buprenorphine use than would alternatives such as opening new substance abuse treatment facilities or raising the overall number of waivered physicians.
Keywords: buprenorphine; health policy; opioid-related disorders; substance abuse treatment.
© 2015 Milbank Memorial Fund.
Similar articles
-
U.S. trends in the supply of providers with a waiver to prescribe buprenorphine for opioid use disorder in 2016 and 2018.Drug Alcohol Depend. 2019 Nov 1;204:107527. doi: 10.1016/j.drugalcdep.2019.06.029. Epub 2019 Aug 30. Drug Alcohol Depend. 2019. PMID: 31525570
-
Supply of buprenorphine waivered physicians: the influence of state policies.J Subst Abuse Treat. 2015 Jan;48(1):104-11. doi: 10.1016/j.jsat.2014.07.010. Epub 2014 Aug 2. J Subst Abuse Treat. 2015. PMID: 25218919 Free PMC article.
-
The effect of Medicaid expansion on use of opioid agonist treatment and the role of provider capacity constraints.Health Serv Res. 2020 Jun;55(3):383-392. doi: 10.1111/1475-6773.13282. Epub 2020 Mar 12. Health Serv Res. 2020. PMID: 32166761 Free PMC article.
-
Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians.Rural Remote Health. 2015;15:3019. Epub 2015 Feb 4. Rural Remote Health. 2015. PMID: 25651434 Review.
-
Buprenorphine for office-based treatment of patients with opioid addiction.J Am Osteopath Assoc. 2005 Jun;105(6 Suppl 3):S8-13. J Am Osteopath Assoc. 2005. PMID: 16118361 Review.
Cited by
-
Buprenorphine Treatment For Opioid Use Disorder: Comparison Of Insurance Restrictions, 2017-21.Health Aff (Millwood). 2023 May;42(5):658-664. doi: 10.1377/hlthaff.2022.01513. Health Aff (Millwood). 2023. PMID: 37126752 Free PMC article.
-
Trends in Geographic Proximity to Substance Use Disorder Treatment.Am J Prev Med. 2023 Oct;65(4):618-626. doi: 10.1016/j.amepre.2023.03.019. Epub 2023 Apr 8. Am J Prev Med. 2023. PMID: 37037326
-
Federal pharmacist Paxlovid prescribing authority: A model policy or impediment to optimal care?Explor Res Clin Soc Pharm. 2023 Mar;9:100244. doi: 10.1016/j.rcsop.2023.100244. Epub 2023 Mar 14. Explor Res Clin Soc Pharm. 2023. PMID: 36945228 Free PMC article.
-
I Don't Believe a Person Has to Die When Trying to Get High: Overdose Prevention and Response Strategies in Rural Illinois.Int J Environ Res Public Health. 2023 Jan 16;20(2):1648. doi: 10.3390/ijerph20021648. Int J Environ Res Public Health. 2023. PMID: 36674402 Free PMC article.
-
Sociodemographic differences in quality of treatment to Medicaid enrollees receiving buprenorphine.Subst Abus. 2022 Dec;43(1):1057-1071. doi: 10.1080/08897077.2022.2060424. Subst Abus. 2022. PMID: 35442178 Free PMC article.
References
-
- Office of Applied Studies SAMHSA. The DASIS report. The national survey of substance abuse treatment services (N‐SSATS). 2012. http://www.oas.samhsa.gov/2k3/NSSATS/NSSATS.pdf. Accessed June 23, 2013.
-
- Murphy S, Xu J, Kochanek K. Deaths: final data for 2010. Natl Vital Stat Rep. 2013;61(4). - PubMed
-
- Birnbaum HG, White AG, Schiller M, Waldman T, Cleveland JM, Roland CL. Societal costs of prescription opioid abuse, dependence, and misuse in the United States. Pain Med. 2011;12(4):657‐667. - PubMed
-
- Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2008(2). - PubMed
-
- National Institute on Drug Abuse. Principles of Effective Treatment for Criminal Justice Populations. Rockville, MD: National Institute on Drug Abuse; 2006.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous